17.10
price down icon3.88%   -0.69
after-market アフターアワーズ: 17.00 -0.10 -0.58%
loading
前日終値:
$17.79
開ける:
$17.82
24時間の取引高:
9.86M
Relative Volume:
2.60
時価総額:
$1.81B
収益:
$2.18B
当期純損益:
$-64.32M
株価収益率:
-17.74
EPS:
-0.9641
ネットキャッシュフロー:
$91.18M
1週間 パフォーマンス:
-4.20%
1か月 パフォーマンス:
-13.46%
6か月 パフォーマンス:
-19.23%
1年 パフォーマンス:
-26.74%
1日の値動き範囲:
Value
$16.85
$17.84
1週間の範囲:
Value
$16.37
$18.14
52週間の値動き範囲:
Value
$14.68
$24.68

Sarepta Therapeutics Inc Stock (SRPT) Company Profile

Name
名前
Sarepta Therapeutics Inc
Name
セクター
Healthcare (1052)
Name
電話
617-274-4000
Name
住所
215 FIRST STREET, CAMBRIDGE, MA
Name
職員
835
Name
Twitter
@sarepta
Name
次回の収益日
2026-11-02
Name
最新のSEC提出書
Name
SRPT's Discussions on Twitter

Compare SRPT vs VRTX, MRNA, REGN, ARGX, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
SRPT icon
SRPT
Sarepta Therapeutics Inc
17.10 1.81B 2.18B -64.32M 91.18M -0.9641
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
499.74 126.66B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
218.01 87.04B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
790.74 81.41B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
819.14 51.51B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
369.06 41.75B 5.76B 514.49M 1.10B 4.4813

Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-07-09 アップグレード Wolfe Research Peer Perform → Outperform
2026-01-28 再開されました Barclays Equal Weight
2025-12-09 開始されました Wedbush Outperform
2025-11-05 アップグレード Mizuho Neutral → Outperform
2025-09-22 アップグレード BMO Capital Markets Market Perform → Outperform
2025-07-29 アップグレード Barclays Underweight → Equal Weight
2025-07-29 開始されました Bernstein Mkt Perform
2025-07-29 繰り返されました H.C. Wainwright Sell
2025-07-29 アップグレード JP Morgan Underweight → Neutral
2025-07-29 アップグレード Oppenheimer Perform → Outperform
2025-07-28 ダウングレード Barclays Equal Weight → Underweight
2025-07-25 ダウングレード JP Morgan Neutral → Underweight
2025-07-24 開始されました Citigroup Sell
2025-07-23 ダウングレード BofA Securities Neutral → Underperform
2025-07-22 ダウングレード Barclays Overweight → Equal Weight
2025-07-21 ダウングレード Deutsche Bank Buy → Hold
2025-07-21 ダウングレード Leerink Partners Outperform → Market Perform
2025-07-21 ダウングレード Mizuho Outperform → Neutral
2025-07-21 ダウングレード Needham Hold → Underperform
2025-07-21 ダウングレード UBS Buy → Neutral
2025-07-18 ダウングレード Needham Buy → Hold
2025-06-20 ダウングレード William Blair Outperform → Mkt Perform
2025-06-18 ダウングレード TD Cowen Buy → Hold
2025-06-17 開始されました Wolfe Research Peer Perform
2025-06-16 ダウングレード BMO Capital Markets Outperform → Market Perform
2025-06-16 ダウングレード BofA Securities Buy → Neutral
2025-06-16 ダウングレード Cantor Fitzgerald Overweight → Neutral
2025-06-16 ダウングレード H.C. Wainwright Neutral → Sell
2025-06-16 ダウングレード Morgan Stanley Overweight → Equal-Weight
2025-06-16 ダウングレード Piper Sandler Overweight → Neutral
2025-06-06 アップグレード Scotiabank Sector Perform → Sector Outperform
2025-05-08 ダウングレード Evercore ISI Outperform → In-line
2025-04-11 開始されました Wells Fargo Overweight
2025-04-02 アップグレード H.C. Wainwright Sell → Neutral
2025-03-31 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2025-02-11 開始されました Deutsche Bank Hold
2024-11-27 繰り返されました Needham Buy
2024-11-25 開始されました H.C. Wainwright Sell
2024-11-07 アップグレード Cantor Fitzgerald Neutral → Overweight
2024-10-21 開始されました Jefferies Buy
2024-10-10 再開されました Raymond James Outperform
2024-07-29 アップグレード RBC Capital Mkts Sector Perform → Outperform
2024-06-26 ダウングレード Citigroup Buy → Neutral
2024-05-31 開始されました Piper Sandler Overweight
2024-05-28 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2024-05-14 アップグレード Oppenheimer Perform → Outperform
2024-01-31 開始されました BMO Capital Markets Outperform
2023-12-13 再開されました Citigroup Buy
2023-12-12 開始されました Deutsche Bank Buy
2023-11-21 開始されました Wedbush Outperform
2023-10-31 ダウングレード Cantor Fitzgerald Overweight → Neutral
2023-10-31 ダウングレード Oppenheimer Outperform → Perform
2023-06-23 ダウングレード Evercore ISI Outperform → In-line
2023-04-26 開始されました SMBC Nikko Outperform
2023-04-04 開始されました Citigroup Buy
2023-03-01 アップグレード Morgan Stanley Equal-Weight → Overweight
2022-12-22 繰り返されました BTIG Research Buy
2022-12-16 アップグレード UBS Neutral → Buy
2022-04-04 再開されました Cantor Fitzgerald Overweight
2022-01-05 繰り返されました Needham Buy
2021-12-09 アップグレード Oppenheimer Perform → Outperform
2021-11-05 アップグレード JP Morgan Neutral → Overweight
2021-09-15 アップグレード Guggenheim Neutral → Buy
2021-08-05 アップグレード JP Morgan Underweight → Neutral
2021-06-15 開始されました BTIG Research Buy
2021-04-26 再開されました Credit Suisse Neutral
2021-01-12 ダウングレード Citigroup Buy → Neutral
2021-01-11 ダウングレード UBS Buy → Neutral
2021-01-08 ダウングレード JP Morgan Overweight → Underweight
2021-01-08 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-01-08 ダウングレード Raymond James Outperform → Mkt Perform
2020-11-11 開始されました Berenberg Hold
2020-10-28 開始されました UBS Buy
2020-08-25 開始されました Raymond James Outperform
2020-08-20 ダウングレード Credit Suisse Outperform → Neutral
2020-03-31 開始されました Mizuho Buy
2019-11-01 開始されました Guggenheim Buy
2019-08-21 繰り返されました Needham Buy
2019-07-09 繰り返されました Morgan Stanley Overweight
2019-07-01 繰り返されました RBC Capital Mkts Outperform
2019-04-12 開始されました Evercore ISI Outperform
2019-03-11 繰り返されました Credit Suisse Outperform
2018-10-12 開始されました Bernstein Outperform
2018-10-01 開始されました Cantor Fitzgerald Overweight
2018-09-26 繰り返されました RBC Capital Mkts Outperform
2018-09-14 再開されました BofA/Merrill Buy
2018-09-06 開始されました Credit Suisse Outperform
2018-08-01 アップグレード Morgan Stanley Equal-Weight → Overweight
2018-06-21 繰り返されました Robert W. Baird Outperform
2018-06-20 繰り返されました Needham Buy
2018-06-19 繰り返されました H.C. Wainwright Buy
すべてを表示

Sarepta Therapeutics Inc (SRPT) 最新ニュース

pulisher
Oct 06, 2026

Top Research Reports for SpaceX, Dell & KLA Corp. - Zacks Investment Research

Oct 06, 2026
pulisher
Sep 30, 2026

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Sep 30, 2026
pulisher
Sep 30, 2026

A treatment was linked to better movement over 2 years in boys ages 8 to 12 with Duchenne - Stock Titan

Sep 30, 2026
pulisher
Sep 26, 2026

LB Pharmaceuticals Inc (LBRX) Stock Price & News - Syfe

Sep 26, 2026
pulisher
Sep 25, 2026

Neurogene Inc. (NGNE) Stock Price & News - Syfe

Sep 25, 2026
pulisher
Sep 15, 2026

Sarepta Therapeutics, Inc.Common Stock (NQ: SRPT - The Chronicle-Journal

Sep 15, 2026
pulisher
Sep 10, 2026

Sarepta Therapeutics Drops 5.5% Amid Sector-Wide Selling - AlphaStreet

Sep 10, 2026
pulisher
Sep 10, 2026

Sarepta Therapeutics Drops 5.5% Amid Sector-Wide Selling - AlphaStreet

Sep 10, 2026
pulisher
Sep 09, 2026

SRPT Looks 79.1% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus

Sep 09, 2026
pulisher
Sep 09, 2026

Sarepta Therapeutics climbs 10%, rebounding from recent slide (SRPT:NASDAQ) - Seeking Alpha

Sep 09, 2026
pulisher
Sep 09, 2026

Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving High - Benzinga

Sep 09, 2026
pulisher
Sep 09, 2026

IRWD Stock Price, Quote & News - Syfe

Sep 09, 2026
pulisher
Sep 09, 2026

H.C. Wainwright reiterates Sarepta stock Sell rating at $5 target By Investing.com - Investing.com Canada

Sep 09, 2026
pulisher
Sep 09, 2026

AQST Stock Price, Quote & News - Syfe

Sep 09, 2026
pulisher
Sep 08, 2026

Sarepta (NASDAQ: SRPT) CFO now holds 121,792 shares after tax withholding - Stock Titan

Sep 08, 2026
pulisher
Sep 08, 2026

Tax on stock award trims Sarepta (NASDAQ: SRPT) EVP stake to 115,519 shares - Stock Titan

Sep 08, 2026
pulisher
Sep 08, 2026

Sarepta (SRPT) COO reports tax share withholding after RSU vesting - Stock Titan

Sep 08, 2026
pulisher
Sep 08, 2026

Jefferies reiterates Sarepta Therapeutics stock rating on trial data outlook By Investing.com - Investing.com South Africa

Sep 08, 2026
pulisher
Sep 08, 2026

Jefferies reiterates Sarepta Therapeutics stock rating on trial data outlook By Investing.com - Investing.com Canada

Sep 08, 2026
pulisher
Sep 08, 2026

Jefferies reiterates Sarepta Therapeutics stock rating on trial data outlook - Investing.com India

Sep 08, 2026
pulisher
Sep 08, 2026

Jefferies reiterates Sarepta Therapeutics stock rating on trial data outlook By Investing.com - Investing.com UK

Sep 08, 2026
pulisher
Sep 08, 2026

A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower - Benzinga

Sep 08, 2026
pulisher
Sep 08, 2026

Mizuho reiterates Sarepta stock rating after Novartis trial miss By Investing.com - Investing.com South Africa

Sep 08, 2026
pulisher
Sep 08, 2026

Mizuho reiterates Sarepta stock rating after Novartis trial miss By Investing.com - Investing.com Nigeria

Sep 08, 2026
pulisher
Sep 08, 2026

Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Reuters

Sep 08, 2026
pulisher
Sep 08, 2026

Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Yahoo Finance

Sep 08, 2026
pulisher
Sep 08, 2026

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year - BioSpace

Sep 08, 2026
pulisher
Sep 08, 2026

Why is Sarepta Therapeutics stock sliding today? By Investing.com - Investing.com Canada

Sep 08, 2026
pulisher
Sep 08, 2026

Why is Sarepta Therapeutics stock sliding today? By Investing.com - Investing.com India

Sep 08, 2026
pulisher
Sep 08, 2026

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year - Business Wire

Sep 08, 2026
pulisher
Sep 08, 2026

Why is Sarepta Therapeutics stock sliding today? - Investing.com

Sep 08, 2026
pulisher
Sep 08, 2026

Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga

Sep 08, 2026
pulisher
Sep 08, 2026

Novartis drops 13% on trial failure, dragging Dyne and Sarepta (NVS:NYSE) - Seeking Alpha

Sep 08, 2026
pulisher
Sep 07, 2026

Sarepta Therapeutics (SRPT) Stock Analysis: Navigating the Biotech Landscape with Innovative Therapies - DirectorsTalk Interviews

Sep 07, 2026
pulisher
Sep 05, 2026

Sarepta Therapeutics Faces Investor Investigations – 8-5 - stl.news

Sep 05, 2026
pulisher
Sep 04, 2026

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc.SRPT - PR Newswire

Sep 04, 2026
pulisher
Sep 04, 2026

Why Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report? - Yahoo Finance

Sep 04, 2026
pulisher
Aug 31, 2026

Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - finance.yahoo.com

Aug 31, 2026
pulisher
Aug 31, 2026

Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Potential Upside In Biotech Amidst Revenue Challenges - DirectorsTalk Interviews

Aug 31, 2026
pulisher
Aug 29, 2026

Sarepta Therapeutics (SRPT) Could Be 30% Undervalued After Elevidys Progress Hopes - Sahm

Aug 29, 2026
pulisher
Aug 28, 2026

CytomX Therapeutics, Inc. (CTMX) Stock Price & News - Syfe

Aug 28, 2026
pulisher
Aug 28, 2026

Sarepta Therapeutics (SRPT) Could Be 30% Undervalued After Elevidys Progress Hopes - simplywall.st

Aug 28, 2026
pulisher
Aug 28, 2026

Sarepta: A Prove-It Story Now Defined By ELEVIDYS Execution - Seeking Alpha

Aug 28, 2026
pulisher
Aug 27, 2026

SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data — Retail Eyes ‘Monumental Comeback’ - Stocktwits

Aug 27, 2026
pulisher
Aug 25, 2026

Sarepta (SRPT) Stock Looks Fully Valued As Sales Trail Fair Value - Yahoo Finance

Aug 25, 2026
pulisher
Aug 24, 2026

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc.SRPT - Business Wire

Aug 24, 2026
pulisher
Aug 19, 2026

Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 9.2%Here's Why - MarketBeat

Aug 19, 2026
pulisher
Aug 19, 2026

Sarepta Therapeutics Delivers Q2 Operating Profit as CEO Transition Advances Pipeline - Streetwise Reports

Aug 19, 2026
pulisher
Aug 19, 2026

Sarepta Therapeutics Jumps 8.6% Amid Sector-Wide Rally - AlphaStreet

Aug 19, 2026
pulisher
Aug 19, 2026

Sarepta Therapeutics Delivers Q2 Operating Profit as CEO Transition Advances Pipeline - Streetwise Reports

Aug 19, 2026

Sarepta Therapeutics Inc (SRPT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Sarepta Therapeutics Inc (SRPT) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
STEPHEN MAYO
Director
Mar 12 '26
Proposed Sale
17.02
7,239
123,175
0
Estepan Ian Michael
Chief Operating Officer
Feb 26 '26
Option Exercise
13.71
7,450
102,140
200,750
Nicaise Claude
Director
Jan 29 '26
Option Exercise
13.71
10,500
143,955
38,312
BEHRENS M KATHLEEN
Director
Jan 27 '26
Option Exercise
13.71
10,500
143,955
203,976
Estepan Ian Michael
Chief Operating Officer
Dec 16 '25
Sale
22.31
13,187
294,202
193,300
IAN M ESTEPAN
Officer
Dec 16 '25
Proposed Sale
22.31
13,187
294,145
0
$25.03
price down icon 2.80%
$20.30
price down icon 6.19%
$11.26
price down icon 12.17%
$3.465
price down icon 16.71%
$31.32
price down icon 3.09%
$120.30
price down icon 5.53%
大文字化:     |  ボリューム (24 時間):